SubsidieMeestersRuthenium-containing Polymers against Ovarian Cancers
This project aims to enhance survival rates in advanced ovarian cancer by validating a novel ruthenium-based drug delivery system in patient-derived xenograft models to overcome platinum resistance.
Projectdetails
Introduction
Nearly 250,000 women are diagnosed each year with ovarian cancer around the world, resulting in 140,000 deaths. High-grade epithelial ovarian cancer (EOC) is the deadliest gynecologic cancer, ranking fifth overall in cancer deaths.
Diagnosis and Survival Rates
The majority of women have widespread intra-abdominal disease at the time of diagnosis, and the 5-year survival rate for these women is only about 40% after receiving standard therapy. Currently, the standard first-line treatment for ovarian cancer consists of surgical cytoreduction and platinum-based chemotherapy.
Challenges in Treatment
Although this approach has proven to be the most effective treatment to date, many ovarian cancers exhibit primary platinum resistance, and most patients develop secondary platinum resistance during the course of their disease. There is therefore a paucity of approved targeted therapies. Accordingly, effective novel therapies are needed to improve survival rates for patients diagnosed with ovarian cancer, especially in its advanced stages and in the setting of platinum resistance.
Research on Metal-Based Anticancer Drugs
The phenomenal success of cisplatin, oxaliplatin, and carboplatin has boosted the research directed at novel metal-based anticancer drugs. My group has embarked a few years ago into a program to thoroughly investigate Ru compounds as anticancer drug candidates.
Addressing Toxicity Issues
However, one serious problem of metal-based drugs is often their intrinsic toxicity. To tackle this issue and circumvent these limitations, macromolecular delivery systems can be used to improve the potential of the respective anticancer ruthenium complexes.
Innovative Methodology
During the frame of the ERC consolidator grant PhotoMetMed, my group could demonstrate that an innovative drug-initiated polymerization methodology could be used to tackle this problem.
Future Directions
In this proposal, to further demonstrate that this technology could be used on humans, the in vivo efficacy of this system will be validated in several ovarian cancer Patient-Derived Xenografts (PDXs) models.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-9-2023 |
| Einddatum | 28-2-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARISpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Macrophage-based immunotherapy of platinum-resistant ovarian cancerThe MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies. | EIC Transition | € 2.499.998 | 2022 | Details |
Catalysis for Cancer Treatment.Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges. | ERC SyG | € 10.603.994 | 2024 | Details |
What doesn’t kill you: primed and adaptive mechanisms of treatment resistance in ovarian cancerThis project aims to develop a novel methodology to identify and target pre-existing resistant cell states in ovarian cancer, enhancing therapy effectiveness through sequential drug combinations. | ERC COG | € 1.999.754 | 2024 | Details |
Innovative Photoactivated Ruthenium Chemotherapy to treat eye cancerPACT4EYE aims to develop a novel photoactivated chemotherapy using a ruthenium prodrug to treat uveal melanoma, enhancing patient outcomes by targeting tumors in hypoxic conditions. | EIC Transition | € 2.499.998 | 2023 | Details |
Macrophage-based immunotherapy of platinum-resistant ovarian cancer
The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.
Catalysis for Cancer Treatment.
Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges.
What doesn’t kill you: primed and adaptive mechanisms of treatment resistance in ovarian cancer
This project aims to develop a novel methodology to identify and target pre-existing resistant cell states in ovarian cancer, enhancing therapy effectiveness through sequential drug combinations.
Innovative Photoactivated Ruthenium Chemotherapy to treat eye cancer
PACT4EYE aims to develop a novel photoactivated chemotherapy using a ruthenium prodrug to treat uveal melanoma, enhancing patient outcomes by targeting tumors in hypoxic conditions.